--News Direct--

Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials.

SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness.

Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.

Contact Details

Proactive Investors US

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/skye-bioscience-marks-sbi-100-clinical-trial-progress-with-new-clinical-research-organization-243499754